From: New genes in the evolution of the neural crest differentiation program
Group | Gene |
---|---|
Deuterostomia | Brain derived neurotrophic factor |
 | Fanconi anemia, complementation group A |
 | Fos-like antigen 2 |
 | Neurotropin 3 |
 | Noggin |
 | Purinergic receptor P2X, ligand-gated ion channel, 7 |
 | Rod outer segment membrane protein 1 |
Vertebrata | BCL2-like 11 (apoptosis facilitator) |
 | Calcitonin/calcitonin-related polypeptide, alpha |
 | Cocaine and amphetamine regulated transcript |
 | Endothelin 1 |
 | Endothelin 3 |
 | Formin 1 |
 | Glial cell line derived neurotrophic factor |
 | Gonadotropin releasing hormone 1 |
 | Hermansky-Pudlak syndrome 6 |
 | Integrin, alpha 10 |
 | Islet amyloid polypeptide |
 | Leukocyte cell derived chemotaxin 1 |
 | Matrix Gla protein |
 | Melanoma inhibitory activity 1 |
 | Myelin protein zero |
 | Natriuretic peptide precursor type C |
 | Neuregulin 1 |
 | Neurturin |
 | Parathyroid hormone |
 | Parathyroid hormone-like peptide |
 | Phosphodiesterase 6G, cGMP-specific, rod, gamma |
 | Pro-opiomelanocortin-alpha |
 | Silver |
 | Tenomodulin |
 | Treacher Collins Franceschetti syndrome 1, homolog |
Chordata | Activating transcription factor 4 |
 | Cbp/p300-interacting transactivator, with Glu/Asp-rich carboxy-terminal domain, 2 |
 | Claudin 14 |
 | Epilepsy, progressive myoclonic epilepsy, type 2 gene alpha |
 | Fos-like antigen 1 |
 | Gap junction membrane channel protein beta 6 |
 | Hyaluronan and proteoglycan link protein 1 |
 | Transforming growth factor, beta receptor III |
Mammalia | Adrenocortical dysplasia |
 | Ameloblastin |
 | Amelogenin X chromosome |
 | BH3 interacting domain death agonist |
 | Colony stimulating factor 2 (granulocyte-macrophage) |
 | Harakiri, BCL2 interacting protein (contains only BH3 domain) |
 | Kit ligand |
 | Leptin |
 | Matrix extracellular phosphoglycoprotein with ASARM motif (bone) |
 | MyoD family inhibitor |
 | Nonagouti |
 | Oncostatin M |
 | Programmed cell death 1 |
 | TYRO protein tyrosine kinase binding protein |